Should we consider MMF therapy after rituximab for nephrotic syndrome?
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Guido Filler & Shih-Han Susan Huang & Ajay P. Sharma
- چاپ و سال / کشور: 2011
Description
The management of steroid-dependent nephrotic syndrome, especially in patients who have failed to respond to cytotoxic drugs, such as cyclophosphamide, remains challenging. Rituximab represents a new (off-label) therapeutic option. In a significant portion of patients, it has a short serum half-life following the recovery of CD20- positive cells. The addition of mycophenolate mofetil (MMF) as a maintenance therapy is also an attractive option, but one which requires testing in a prospective randomized clinical trial with therapeutic drug monitoring and mechanistic ancillary studies.
Pediatr Nephrol DOI 10.1007/s00467-011-1894-x Received: 6 April 2011 / Accepted: 6 April 2011
